{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"The primary objective of this study is to determine the complete response rate of lenalidomide and low-dose dexamethasone versus that of lenalidomide and low-dose dexamethasone followed by autologous peripheral blood stem cell transplant in patients with newly diagnosed multiple myeloma (will include unconfirmed complete response (CR), CR and stringent complete response (sCR)).","groups":[{"description":"Subjects will receive the current standard of care treatment. Lenalidomide and dexamethasone for four 28-day cycles followed by stem cell collection and autologous peripheral blood stem cell transplant. After 90 days, start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).","id":"OG000","title":"Arm A: Low-dose Dexamethasone + Stem Cell Transplantation"},{"description":"Subjects will receive the new treatment that will be compared with the standard of care. Lenalidomide and dexamethasone for eight 28-day cycles. After four cycles your stem cells will be collected (stem cell collection). After an additional four cycles of lenalidomide (a total of 8 cycles), start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).","id":"OG001","title":"Arm B: Low-dose Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 participant in Arm B never started treatment.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Complete Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}